Sartorius Launches Next-generation Platform To Boost Efficiency In Cell Therapy Production

The life subject group Sartorius is launching an integrated strategy for nan accumulation and value power (QC) of autologous compartment therapies. The modular Eveo Cell Therapy Platform is designed to reside structural manufacturing bottlenecks that limit scalability and diligent entree to transformative treatments specified arsenic CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally caller attack to compartment therapy accumulation that strengthens nan company’s position successful nan move precocious therapies market.

Image Credit: Sartorius

Cell therapies are redefining aesculapian possibilities. Yet, they stay accessible to only a mini stock of patients because manufacturing is complex, capacity-constrained and truthful expensive. With our integrated platform, we are tackling these structural bottlenecks head-on, By combining earthy materials, accumulation equipment, package and QC assays into a scalable system, we alteration our customers to grow output, importantly trim costs per dose and shorten vein-to-vein clip for patients.”

René Fáber, Member of nan Executive Board, Sartorius

Conventional manufacturing models for autologous compartment therapies trust connected centralized, purpose-built facilities, that require important greenfield investment, unit recruitment, training and multi-year build-up phases. Nevertheless, astir 60 percent of regulatory disruptions successful compartment therapy accumulation are caused by manufacturing and process-related issues.

The caller Eveo level addresses these challenges by integrating compartment selection, activation, cistron modification, description , lavation and attraction and last formulation into a closed system, utilizing a variety of Sartorius solutions from captious earthy materials to bioreactors and separation technologies. The system’s compact design supports implementation successful existing accommodation pinch existing staff, allows for cognition successful lower-classification environments and supports centralized and decentralized manufacturing models. 

Sartorius has collaborated pinch ElevateBio, a starring compartment therapy CDMO, amongst different partners, to trial retired nan Eveo platform. In a successful pilot, nan strategy performed successful statement pinch creation expectations, demonstrating its real-world applicability. Due to its multi-parallel configuration, a azygous usability tin process 8 diligent batches astatine erstwhile successful nan aforesaid cleanroom abstraction traditionally needed for 2 batches. Assuming a manufacturing clip of astir 7 days per batch and 50 accumulation weeks per year, Eveo enables accumulation of much than 350 doses per year in a footprint that coming yields astir 100 doses – an almost fourfold increase. Financial modelling confirms that nan level tin reduce manufacturing costs by astir 90 percent.

Quality power besides represents a awesome bottleneck successful compartment therapy accumulation and release. With Sartorius’ capabilities successful unrecorded compartment imaging and precocious throughput travel cytometry included successful nan Eveo platform, nan exertion addresses cardinal analytical challenges and enables accessibility.

Sartorius plans to statesman taking orders for the Eveo Cell Therapy Platform successful September 2026, pinch first deliveries expected successful 2027. ElevateBio is simply a preferred partner and will beryllium granted entree to 1 of nan first Eveo platforms for usage pinch its manufacturing customers.